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Available online xxxxIntroduction: Childhood obesity is associated with cardiovascular abnormalities but little is known on the
potential correlation between early cardiovascular and metabolic alterations.
Aim: Aims of this study were 1) to evaluate early cardiovascular abnormalities in a large population of obese
children and adolescents compared with a normal weight counterpart, 2) to investigate their potential associa-
tion with insulin resistance (IR), serum uric acid (sUA) and metabolic syndrome (MetS).
Methods: This was a single-center case-control study. Eighty obese (OB) subjects (6–16 years) and 20 normal
weight (NW)matched controls were consecutively recruited. In the whole population we performed an anthro-
pometric and a cardiovascular assessment. OB patients also underwent an OGTT and biochemical evaluations.
Results:OB children showed greater left atrial (LA) and ventricular (LV) dimensions andmass and higher carotid
artery intima-media thickness (CIMT), comparedwithNWcontrols. The BMI z-score, waist circumference, IR and
sUAwere positively relatedwith LA and LV dimensions andmass. OB subjectswithMetS (46.3%) showed greater
LA diameter (p = 0.001) and LV area (p = 0.01) and volume (p = 0.04) compared with OB children without
MetS. LA diameter and LV dimensions and mass were significantly dependent on the number of criteria for
MetS. Mets, sUA and IR were significant predictors of left heart dimensions and mass in obese children.
Conclusions: Obesity and MetS are associated with abnormal cardiovascular response during childhood.
Hyperuricemia can be an earlymarker of cardiovascular dysfunction and the routine determination of circulating
levels of sUA should be implemented during risk stratification among pediatric age.
© 2017 Elsevier Ireland Ltd. All rights reserved.Keywords:
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Childhood obesity causes a wide range of severe complications,
increasing the risk of premature morbidity and mortality [1]. In addi-
tion, obese children aremore prone to becomeobese adults, with higher
risk of cardiovascular diseases (CVD) [2]. A cluster of CVD risk factors
has been identified in children as young as 5 years of age [3] and,
among adolescents, their presence correlates with asymptomatic
coronary atherosclerosis [4]. Pediatric obesity has been related to anrientale, Department of Health
ovara, Italy.
zani).
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/dx.doi.org/10.1016/j.ijcard.20impaired cardiac structure and function as left atrial (LA) and left
ventricular (LV) dimensions and mass significantly greater than lean
controls [5–8] and impaired diastolic and systolic function [6,9].
Atherogenesis and arterial wall damage begin during childhood and,
there is evolving evidence that clinical indicators of atherosclerosis such
as carotid artery intima-media thickness (CIMT), arterial stiffness, and
endothelial function are altered in obese children [10,11].
Hyperuricemia has been recognized as a risk factor for CVD in adults
being predictive of insulin resistance (IR), metabolic syndrome (MetS)
and all its components [12]. However, little is known on the potential
association between early cardiovascular alterations and hyperuricemia
and MetS in obese children.
The detection of a high cardiovascular risk profile associated with
pediatric obesity and the identification of possible early markers of car-
diovascular damage during childhood would let an early diagnosis ofd andmetabolic syndrome are linked to cardiovascular dysfunction in
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2 G. Genoni et al. / International Journal of Cardiology xxx (2017) e97157cardiovascular complications allowing prompt preventive therapeutic
measures that might reduce cardiovascular morbidity and mortality at
long term follow up.
Therefore, aimsof this studywere 1) to evaluate early cardiovascular
abnormalities in obese children and adolescents compared with a
normal weight counterpart, 2) to investigate their potential association
with IR, serum uric acid (sUA) and MetS.
2. Subjects and methods
2.1. Study design and population
This was a single-center longitudinal case-control study conducted at Division of
Pediatrics in Piedmont Region, Italy. We consecutively enrolled 80 Caucasian obese (OB)
children and adolescents, aged 6–16 years, and 20 normal weight, age and sex matched
controls (NW). OB patients were eligible if they were generally healthy, obese according
to the InternationalObesity Task Force (IOTF) criteria [13], andnot on aweight-loss diet. Ex-
clusion criteria were specific causes of endocrine or genetic obesity, type 1 or type 2 diabe-
tes, previous heart, respiratory, liver andkidney diseases, current or past use of hormonal or
interfering therapies (lipid-lowering, hypoglycemic, or antihypertensive treatments).
Control subjects were eligible if they were normal weight [13], with no history of organic
or psychiatric diseases. The protocol was conducted in accordance with the declaration of
Helsinki and was approved by the Local Ethic Committee (CE 95/12). Informed written
consent was obtained from all subjects' parents.
2.2. Anthropometric and biochemical variables
Height, weight, waist circumference (WC), hip circumference (HC), systolic (SBP) and
diastolic (DBP) blood pressureweremeasured as previously described [14] and bodymass
index (BMI) was calculated. Pubertal stages were evaluated according to Tanner criteria.
In theOB group, after a 12-h overnight fast, blood sampleswere taken formeasurement
of: glucose (mg/dL), insulin (μUI/mL), total cholesterol (mg/dL), high density lipoprotein-
cholesterol (HDL-c, mg/dL), triglycerides (mg/dL), sUA (mg/dL), using standardized
methods in the Hospital's Laboratory [14]. Low density lipoprotein-cholesterol (LDL-c)
was calculated by the Friedwald formula. sUA (mg/dL)wasmeasured by Fossatimethod re-
action using uricase with a Trinder-like endpoint. Obese subjects also underwent an OGTT
(1.75 g of glucose solution per kg, maximum 75 g) and samples were drawn for the
determination of glucose and insulin every 30 min. Insulin-resistance was calculated
using the formula of homeostasis model assessment (HOMA)-IR. Insulin sensitivity at
fasting and during OGTT was calculated as the formula of the Quantitative Insulin-
Sensitivity Check Index (QUICKI) and Matsuda index (ISI) [28]. Glucose was expressed in
mg/dL (1 mg/dL = 0.05551 mmol/L) and insulin in μUI/mL (1 μUI/mL = 7.175 pmol/L) in
each formula [15]. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
were defined according to American Diabetes Association [16] and MetS by using the
modified National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP
III) criteria of Cruz and Goran [17].
2.3. Echocardiographic assessment
Transthoracic echocardiogram using a Vivid 7 Pro ultrasound scanner (General
Electric Healthcare, USA)was performed by a sonographer and the images were reviewed
by an expert pediatric cardiologist, blinded to patients' clinical data. Measurements of left
ventricle (LV end-diastolic diameter, LVEDD; LV end-systolic diameter, LVESD; interven-
tricular septum at end diastole, IVSD; LV posterior wall at end diastole, LVPWD), relative
wall thickness (RWT), left atrium diameter (LAD), the maximum LA volume, and LV
ejection fraction were obtained according to established standards [18]. LV mass (LVM)
was derived from the Devereux formula and indexed to body surface area (left
ventricular mass index [LVMI]) [27]. Using pulsed wave Doppler, mitral inflow velocities,
peak early diastolic velocity (E), peak late diastolic velocity (A), E/A ratio, weremeasured.
Pulsedwave tissue Doppler of the lateral mitral annulus was used for themeasurement of
early peak diastolic mitral annular velocity (E'). The E/E' ratio was calculated.
2.4. Vascular assessment
Vascular measurements were performed with a high-resolution ultrasonography
(Esaote MyLab25™ Gold, Esaote, Italy) using a 8 mHz linear transducer and a 5 mHz con-
vex transducer for the abdominal aorta, by an expert sonographer and images were then
reviewed offline by an expert vascular surgeon blinded to patients' clinical status. CIMT,
abdominal aortic diameter at maximum systolic expansion (Ds) and minimum diastolic
expansion (Dd), brachial artery diameters, brachial artery peak systolic velocity (PSV)
and end diastolic velocity (EDV) were measured as previously described and aortic strain
(S), pressure strain elastic modulus (Ep), pressure strain normalized by diastolic pressure
(Ep*) and brachial artery flow-mediated dilation (FMD) were calculated. While S is the
mean strain of the aortic wall, Ep and Ep* are the mean stiffness [19].
The brachial artery maximum diameter recorded following reactive hyperemia was
reported as a percentage change of resting diameter (FMD = peak diameter− baseline
diameter / baseline diameter) [20].Please cite this article as: G. Genoni, et al., Insulin resistance, serum uric ac
pediatric obesity, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.202.5. Statistical analysis
All data are expressed as mean ± standard deviation (SD), absolute values or
percentages. A sample of 15 individuals has been estimated to be sufficient to demon-
strate a difference of 10% in LV diameter with a SD of 0.44 cm with 90% power and a sig-
nificance level of 95% in the Student t-test between obese and controls according to
published data [6]. A cohort of 75 obese subjects has been estimated to be sufficient to
demonstrate differences among numbers of MetS criteria (0–5 criteria according to
NCEP-ATPII classification) [17]. Distributions of continuous variables were examined for
skewness and were logarithmically transformed as appropriate. ANCOVAwas used to de-
termine the differences between obese and control subjects. Covariates were sex, age and
pubertal stage. Correlation of cardiovascular parameters with continuous values of BMI z-
score, WC, HOMA-IR, ISI, and sUA were examined using Pearson correlation coefficients.
Partial correlation was used to correct for covariates. The stepwise regression model
with two-tailed probability values and 95% confidence intervals was used to measure
the strength of the association between cardiovascular variables and BMI z-score and
each specific MetS criteria (abdominal obesity, hypertension, hypertrygliceridemia, low
HDL-c, glucose intolerance: model 1) and other metabolic impairments (Model 2:
model 1 + sUA; Model 3: model 2 + HOMA-IR). Statistical significance was assumed at
p b 0.05. The statistical analysis was performed with SPSS for Windows version 17.0
(SPSS Inc., Chicago, IL, USA).3. Results
3.1. Anthropometric and cardiovascular characteristics
Table 1 shows the auxological and cardiovascular data of the 80
OB (age 11.2 ± 2.7 yrs., 47.5% females, 36.3% prepubertal, BMI z-
score 2.32 ± 0.51) and 20 age-, sex- and pubertal status-matched
NW subjects (age 10.9 ± 2.5 yrs., 60.0% females, 45.0% prepubertal,
BMI z-score− 0.76 ± 0.98). After adjusting for age, sex and puberty,
OB children showed greater LV dimensions (LVEDD p b 0.02, LVESD
p b 0.02, IVSD p b 0.0001, LVPWD p b 0.001), area (p b 0.0001),
volume (p b 0.002) and LVM (p b 0.0001), LAD (p b 0.005) and
lower E/A ratio (p b 0.005) compared with NW subjects. No differ-
ences were found in the E/E' ratio, LV systolic function, LVMI and
RWT. OB patients had larger abdominal aortic (p b 0.03) and brachial
artery (p b 0.006) diameters compared with NW controls. CIMT was
significantly higher in the OB group (p b 0.0001) while no difference
between the two groups was shown in aortic strain (S) and stiffness
(Ep, Ep*) and in FMD of the brachial artery.3.2. Associations between cardiovascular measurements and metabolic
parameters
In the whole population, after adjusting for age, sex and pubertal
status, both BMI z-score and WC were positively associated with LV
dimensions (LVEDD, LVESD, IVSD, LVPWD), area and volume, LVM,
LVM index, RWT, LAD, CIMT, abdominal aortic and brachial artery
diameters and negatively relatedwith the E/A ratio. A negative relation-
ship was found between BMI z-score and aortic stiffness.
After adjusting for age, sex and puberty, insulin-resistance at fasting
was positively correlated with LV dimensions (LVEDD, IVSD, LVPWD),
area and volume, LVM and LVMI, RWT, LAD, LA area and volume,
abdominal aortic diameter and negatively with the E/A ratio while
insulin sensitivity during OGTT was negatively related with IVSD,
LVPWD, LVM, RWT, LAD and abdominal aortic diameter.
sUA was directly associated with LVEDD, LVESD, LVM, LV area and
volume, brachial artery diameters and negatively with the E/A ratio,
even after adjustment for confounding factors (Table S1).
Associations between cardiovascular measurements and SBP and
DBP are shown in Table S2 in the supplementary appendix. As
regards lipid profile, after adjustment for confounding factors, total
cholesterol was positively correlated with LVPWD and RWT; HDL-c
was negatively related with LAD; LDL-c was directly associated
with CIMT and triglycerides were positively correlated with LAD.
Total cholesterol, LDL-c and triglycerides were negatively related
with the E/A ratio.id andmetabolic syndrome are linked to cardiovascular dysfunction in
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Table 1
Clinical and cardiovascular data of 80 obese (OB) and 20 normal weight (NW) subjects.
OB NW p Value
Subjects 80 20
Age (years) 11.2 ± 2.7 10.9 ± 2.5 ns
Female 38 (47.5%) 12 (60.0%) ns
Prepubertal 29 (36.3%) 9 (45.0%) ns
Height (cm) 149.6 ± 15.1 145.3 ± 15.3 0.0001
Height (SDS) 1.11 ± 1.21 0.65 ± 1.11 0.03
Weight (kg) 69.3 ± 22.6 36.5 ± 10.3 0.0001
BMI (kg/m2) 30.0 ± 5.2 17.0 ± 2.4 0.0001
BMI z-score 2.32 ± 0.51 −0.76 ± 0.98 0.0001
Waist (cm) 90.2 ± 14.3 60.9 ± 6.6 0.0001
Hip (cm) 96.4 ± 15.0 70.4 ± 9.3 0.0001
N° WC ≥ 90° p 79 (98.7%) 4 (20.0%) 0.001
SBP (mm Hg) 123.7 ± 16.6 105.8 ± 16.1 0.0001
DBP (mm Hg) 78.2 ± 10.8 67.1 ± 8.8 0.0001
N° SBP or DBP ≥ 90° p 68 (78.7%) 6 (30%) 0.001
HR (b/min) 84.2 ± 12.1 78.1 ± 11.4 ns
EF (%) 69.5 ± 8.4 70.8 ± 6.1 ns
FS (%) 40.3 ± 6.7 40.2 ± 5.5 ns
LVEDD (mm) 44.5 ± 0.6 41.2 ± 0.5 0.02
LVESD (mm) 27.4 ± 0.5 24.6 ± 1.2 0.02
IVSD (mm) 7.6 ± 0.2 5.9 ± 0.4 0.0001
LVPWD (mm) 7.8 ± 0.2 6.1 ± 0.5 0.001
LAD (mm) 32.0 ± 0.6 27.8 ± 1.3 0.005
LV area (cm2) 25.8 ± 0.6 19.9 ± 1.4 0.0001
LV volume (mL) 78.6 ± 3.0 56.3 ± 6.3 0.002
LA area (cm2) 13.1 ± 3.7 12.1 ± 3.6 ns
LA volume (mL) 31.2 ± 12.4 29.4 ± 10.9 ns
LV mass (g) 113.3 ± 6.0 74.3 ± 13.4 0.0001
LV mass index (g/m2) 66.9 ± 22.9 62.5 ± 24.2 ns
RWT 0.35 ± 0.08 0.31 ± 0.06 ns
Mitral E peak (cm/s) 102.0 ± 20.1 99.2 ± 10.3 ns
Mitral A peak (cm/s) 58.2 ± 14.1 50.1 ± 11.2 0.03
Mitral E/A ratio 1.8 ± 0.1 2.1 ± 0.1 0.005
Mitral lateral E' velocity (cm/s) 19.6 ± 3.2 19.2 ± 2.1 ns
Mitral lateral E/E' ratio 5.2 ± 0.9 5.1 ± 0.7 ns
CIMT (mm) 0.63 ± 0.02 0.46 ± 0.04 0.0001
AoDs (mm) 12.8 ± 0.2 11.4 ± 0.4 0.006
AoDd (mm) 10.3 ± 0.2 9.3 ± 0.4 0.03
S 0.23 ± 0.12 0.25 ± 0.14 ns
Ep (mm Hg) 459 ± 1170 302 ± 681 ns
Ep* 8.3 ± 24.1 4.0 ± 9.2 ns
BAD basal (mm) 3.5 ± 0.1 3.0 ± 0.1 0.006
BAD after (mm) 3.5 ± 0.1 3.2 ± 0.2 0.04
FMD (%) 3.5 ± 15.6 7.8 ± 13.6 ns
PSV basal (cm/s) 67.2 ± 26.0 71.3 ± 18.9 ns
EDV basal (cm/s) 11.3 ± 6.7 9.3 ± 7.6 ns
PSV immediately after (cm/s) 81.7 ± 27.6 89.2 ± 19.3 ns
EDV immediately after (cm/s) 25.1 ± 10.1 26.5 ± 8.7 ns
PSV after (cm/s) 72.4 ± 27.1 74.6 ± 17.1 ns
EDV afer (cm/s) 13.5 ± 8.0 11.3 ± 6.9 ns
Values are number (%) or means ± SD.
A, peak velocity of late diastolic transmitral wave; after, 2 min after the release of the
pneumatic cuff; AoDd, abdominal aortic diastolic diameter; AoDs, abdominal aortic systol-
ic diameter; BAD brachial artery diameter; BMI, body mass index; CIMT, carotid intima-
media thickness; DBP, diastolic blood pressure; E, peak velocity of early diastolic
transmitral wave; E', peak early diastolic velocity on mitral annulus; EDV, brachial artery
end-diastolic velocity; EF, LV ejection fraction; Ep, pressure strain elastic modulus; Ep*,
pressure strain normalized for DBP; FMD, brachial artery flow-mediated dilation; FS, LV
fractional shortening; HR, heart rate; immediately after, the release of the pneumatic
cuff; IVSD, interventricular septum diastolic dimension; LA, left atrium; LAD, LA end-sys-
tolic diameter; LV, left ventricle; LVEDD, LV end-diastolic dimension, LVESD, LV end-sys-
tolic dimension; LVPW, LV posterior wall diastolic dimension; N°, number of subjects;
ns, not significant; p, percentile; PSV, brachial artery peak systolic velocity; RWT, relative
wall thickness; S, aortic strain; SBP, systolic blood pressure; SDS, standard deviation score;
WC, waist circumference.
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Out of OB children, 37 (46.3%) matched the NCEP ATPIII criteria
for MetS. Patients with MetS had greater LAD (p = 0.001) and LV
area (p = 0.01) and volume (p = 0.04) compared with OB subjects
without MetS.Please cite this article as: G. Genoni, et al., Insulin resistance, serum uric aci
pediatric obesity, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.20LAD and LV area, volume and LVM were significantly dependent on
the number of criteria of MetS. Increasing the number of matched
criteria for MetS, LAD, LV area, volume and LVM significantly increased
(Fig. 1). This correlation persisted after adjustment for HOMA-IR for
LAD, LV area and volume while was lost for LVM.
Stepwise multiple regression analysis showed that BMI z-score,
HDL-c ≤ 10th percentile and triglycerides ≥90th percentile were
independent predictors of LAD (model 1 and 2). In model 3, only BMI
z-score and HDL-c in addition to HOMA-IR were confirmed as
significant predictors of increased LAD. LV area was predicted by BP
≥90th percentile and IGT (model 1). In model 2, only sUA and BP were
significant predictors. Inmodel 3, HOMA-IR andBPwere found as signif-
icant predictors. LV volumewas predicted by IGT and HDL-c ≤ 10th per-
centile (model 1). In model 2 and 3, sUA and HOMA-IR were the only
significant predictors. Finally, LVM was predicted by BMI z-score and
triglycerides ≥90th percentile. In model 2 and 3, BMI z-score, sUA,
HOMA-IR and triglycerides were the only significant predictors.
(Table 2).4. Discussion
In this study, we found that pediatric obesity negatively affected
cardiac remodelling and impaired vascular structure. Furthermore, IR
and sUA and the presence of MetS might play an additional adverse
role during heart remodelling among children and adolescents.4.1. Cardiovascular alterations in pediatric obesity
Our study showedmarked variations in the LA and LV dimensions in
OB children compared to NW. These findings are in line with some
previous studies reporting that LA and LV dimensions are significantly
greater in OB children compared to NW [6,8,10,21]. Several investiga-
tions have also reported greater LVM in OB children [5,6,8,10,22], and
this has been detected as early as 2 years of age [22]. Interestingly, we
found no differences when normalizing LVM to body surface area
between the two groups [9,21] possibly related to the overcorrection
of measurements (normalized for parameters including weight)
required for the obese group. Moreover, hypertrophy and dilatation of
the LV might represent a physiological response to the enhanced
preload and afterload dependent to the increased BMI.
Regarding heart function, we found a significant reduction in the
E/A ratio in the OB group (mainly related to the increased inflow ve-
locities during atrial contraction/A-velocities) and no significant
changes in E'-velocities or in the E/E'-ratio with a preserved global
LV systolic function. Despite the well-known association between
diastolic dysfunction and subsequent impaired systolic functional
changes in the adulthood, this correlation is still conflicting when
applied in pediatric subjects.
The majority of studies, showed no difference between obese and
normal weight children in the peak early mitral inflow velocity
(E) and in the early diastolic mitral velocity assessed with PWTDI (E')
as parameters for diastolic function [7,9,21]. According with our data,
the lack of significant changes in early filling characteristics suggests
an increased dependency of atrial filling related to a decreased LV
early relaxation [9,21].
In line with this, we also found increased systolic and diastolic
abdominal aortic and brachial artery diameters in the OB group, which
might represent an early marker of vascular remodelling.
In fact, the assessment of CIMT is a sensitive clinical marker of
atherosclerosis, predictive of CV morbidity and mortality in the
adulthood and high-risk population. Interestingly, we found greater
CIMT in obese patients, even in younger children, not related to the
pubertal status and mainly due to the exposure to cardiovascular
risk factors.d andmetabolic syndrome are linked to cardiovascular dysfunction in
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Fig. 1. MetS criteria-dependent left atrium diameter (LAD) (mm), left ventricle (LV) area (cm2), LV volume (mL) and LV mass (LVM) (g) in 80 obese children and adolescents. Log
transformation was used for skewed variables (LVM). * p b 0.001; ** p b 0.0001; § p b 0.04. Significance was maintained when the model included homoeostasis model assessment of
insulin resistance (HOMA-IR) as covariates for LAD, LV area and volume while was lost for LVM.
4 G. Genoni et al. / International Journal of Cardiology xxx (2017) e971574.2. Potential mechanisms linking obesity to cardiovascular dysfunction
The excess of adipose tissue, enhanced metabolic activity and the
subsequent increased preload, predispose to LA and LV dilatation, LV
remodelling and hypertrophy as a compensatory mechanism for
systolic and diastolic wall stress [23]. Obesity is associatedwith changes
in the vascular system related to the development of early atherosclero-
sis, arterial hypertension and increase afterload. In this study the BMI z-
score, waist circumference and systemic blood pressure are positively
correlated with increasing CIMT. Surprisingly, we found an inverse
relationship between the BMI z-score and arterial stiffness that might
reflect an early compensatory mechanism depicted by the arteries
that try to contrast the afterload via structural changes (increased
diameter and thickness) before the rise in stiffness.
According to previous data, in our obese population, the HOMA-IR
correlates with increasing heart and aortic dimensions and decreasing
diastolic function while no association was found between IR and
CIMT and arterial stiffness [24]. IR can potentially induce to a decreased
myocardial glucose uptake and increased fatty acid oxidation resulting
in the accumulation of toxic intermediates of fatty acid metabolism
that finally lead to myocardial dysfunction and arteries enlargement.
Furthermore, compensatory hyperinsulinemia induces LV hypertrophy
through binding of insulin to cardiac insulin-like growth factor 1 recep-
tors [25].
In our OB group, MetS was associated with greater heart dimension
and mass with straightforward linear raises when increasing the num-
ber of matched criteria for MetS. Subjects who met the MetS criteria,
presented worst metabolic parameters (dyslipidemia, dysglycemia)
with higher prevalence of hypertension and altered BMI with a signifi-
cant impact on cardiac structural alterations. Our data highlight the
influence of MetS also in the pediatric subset, suggesting the usefulness
of an earlyMetS investigation implementedwith prompt cardiovascular
imaging examination and aggressive therapeutic strategy in the obese
children in order to prevent future cardiovascular dysfunction.
Another interesting finding of the current study is the association
between sUA and cardiovascular adverse remodelling. The associationPlease cite this article as: G. Genoni, et al., Insulin resistance, serum uric ac
pediatric obesity, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.20between sUA and levels of individual MetS components and their clus-
tering has been previously reported [25–27]. The Bogalusa Heart Study
showed that elevated sUA plays a crucial role in the pathogenesis of
MetS with an influence that begins during adolescence, suggesting
that sUA may aid in the early identification and treatment of high risk
individuals for MetS [27]. Indeed, in a group of 299 overweight/obese
children aged 8–18 years from the STYJOBS/EDECTA cohort, sUA was
the best predictor of unhealthy obesity [28]. Furthermore, recent inves-
tigations, has suggested that sUA level is an independent predictor of
hypertension in adulthood [12]. In addition, Viazzi et al. showed that
sUAwas directly related to SBP and DBP independently of puberty, gen-
der, BMI z-score, HOMA and renal function in a cohort of children and
adolescents [29]. These data were confirmed by Feig et al. that showed
a correlation between the reduction of sUA and normalization of
blood pressure in 66% of hyperuricemic adolescents with hypertension,
as compared to 3% in controls [30]. Finally, a reduction in sUA improved
body weight and related CVD risk factors in young patients with
hyperuricemia [31]. Moreover, sUA is an independent risk factor for
heath failure and is associated with increased cardiovascular mortality
in adults and children [12]. Out of our knowledge, this is the first
study that demonstrates an association between sUA and LV volume
and mass that is independent of BMI z-score, MetS and insulin
resistance in a large cohort of obese pediatric patients. Studies conduct-
ed in adult populations suggest that hyperuricemia is associated with
cardiac remodelling and LV hypertrophy and that sUA could be amarker
of subclinical myocardial dysfunction [32], but this data were not fully
confirmed during childhood. Reschke et al. showed, in a population of
49 hypertensive children of which 21 overweight/obese and not
evaluated for the presence of MetS, that 1 mg/dL increase in sUA over
the baseline value was associated with an increase in LVM of 20.2 g.
However, this association was no longer significant after adjustment
for confounding factors [33]. Increased sUA levels may contribute to
the echocardiographic abnormalities associated with obesity through
effects on endothelial dysfunction and inflammation. Although uric
acid seems to have antioxidant activity in the extracellular environ-
ment, once entered the cells, including vascular and heart muscle cellsid andmetabolic syndrome are linked to cardiovascular dysfunction in
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Table 2
Stepwise multiple regression analysis of BMI z-score, metabolic syndrome (MetS)
components, serum uric acid (sUA) and insulin resistance (HOMA-IR) (as independent
variables) on left atrium diameter (LAD), left ventricular (LV) area and volume and Log
LV mass (dependent variables).
Dependent
variable
Significant effects B (95% CI) β p-Value
Model 1
LAD (mm) BMI z-score 2.286 (1.070;3.501) 0.375 b0.0001
HDL-c ≤ 10th p 0.255 (0.036;0.473) 0.229 b0.02
Triglycerides ≥90th p 0.278 (0.023;0.534) 0.218 b0.03
R:0.568
Model 2 (sUA)
LAD (mm) BMI z-score 2.286 (1.070;3.501) 0.375 b0.0001
HDL-c ≤ 10th p 0.255 (0.036;0.473) 0.229 b0.02
Triglycerides ≥90th p 0.278 (0.023;0.534) 0.218 b0.03
R:0.568
Model 3 (HOMA-IR)
LAD (mm) BMI z-score 2.081 (0.828;3.333) 0.341 b0.001
HDL-c ≤ 10th p 0.275 (0.059;0.490) 0.247 b0.01
HOMA-IR 0.042 (0.006;0.077) 0.240 b0.02
R:0.574
Model 1
LV area (cm2) BP ≥90th p 4.395 (1.137;7.653) 0.290 b0.009
IGT 7.016 (1.548;12.484) 0.275 b0.01
R:0.428
Model 2 (sUA)
LV area (cm2) sUA 1.900 (0.928;2.873) 0.402 b0.0001
BP ≥90th p 3.761 (0.636;6.886) 0.248 b0.02
R:0.513
Model 3 (HOMA-IR)
LV area (cm2) HOMA-IR 0.633 (0.207;1.060) 0.316 b0.004
BP ≥90th p 4.150 (0.920;7.379) 0.273 b0.01
R:0.453
Model 1
LV volume (mL) IGT 32.633 (5.271;59.995) 0.266 b0.02
HDL-c ≤ 10th p 14.123 (0.140;28.105) 0.225 b0.05
R:0.365
Model 2 (sUA)
LV volume (mL) sUA 10.284 (5.443;15.125) 0.449 b0.0001
R:0.449
Model 3 (HOMA-IR)
LV volume (mL) sUA 8.177 (3.073;13.281) 0.357 b0.002
HOMA-IR 2.370 (0.189;4.551) 0.242 b0.03
R:0.502
Model 1
Log LV mass (g) BMI z-score 1.003 (0.615;1.390) 0.495 b0.0001
Triglycerides ≥90th p 0.105 (0.023;0.187) 0.245 b0.01
R:0.598
Model 2 (sUA)
Log LV mass (g) BMI z-score 0.765 (0.356;1.174) 0.378 b0.0001
sUA 0.034 (0.009;0.058) 0.276 b0.007
Triglycerides ≥90th p 0.100 (0.021;0.178) 0.233 b0.01
R:0.647
Model 3 (HOMA-IR)
Log LV mass (g) BMI z-score 0.687 (0.279;1.095) 0.339 b0.001
sUA 0.029 (0.004;0.053) 0.235 b0.02
HOMA-IR 0.012 (0.001;0.023) 0.198 b0.04
Triglycerides ≥90th p 0.080 (0.001;0.159) 0.186 b0.05
R:0.671
BP, blood pressure; CI, confidence interval; HDL-c, HDL-cholesterol; IGT, impaired glucose
tolerance; p, percentile.
Model 1: independent variables were BMI z-score and MetS components, (waist
circumference ≥ 90th percentile; BP ≥90th percentile; triglycerides ≥90th percentile;
HDL-c ≤ 10th percentile; impaired fasting glucose; impaired glucose tolerance).
Model 2: independent variables were those of Model 1 plus sUA.
Model 3: independent variables were those of Model 2 plus HOMA-IR.
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impacts of sUA include intracellular reactive oxygen species production,
an inhibitory effect on nitric oxide formation, induction of platelet
aggregation, and pro-inflammatory activity [12], also in children [34].
Furthermore, sUA activates the renin-angiotensin system causing
hypertension. The renin-angiotensin system, in turn, has been proposed
to cause LV hypertrophy and cardiac fibrosis though mechanisms
including BP increase, direct action of angiotensin II on cardiac
myocytes, and effects of aldosterone [32]. As suggested by Borghi and
Cicero, sUA requires more attention in the evaluation of the metabolic
risk profile of obese children and adolescents [35] and, based on our
findings, it could be an early marker of cardiovascular dysfunction in
this population allowing a prompt and effective preventive measures.
4.3. Study limitations
Our study has several potential limitations. The major limit is the
relatively small size of the population. Moreover, our study was not a
randomized controlled trial. We perform a prospective data collection,
which is certainly susceptible to selection bias.
Finally a more extensive use of vascular imaging modalities
including speckle tracking echocardiography and cardiac MRI would
have certainly improved the results of the current study.
5. Conclusion
In conclusion, this study shows that obesity andMetS are associated
with abnormal cardiovascular response during childhood. Moreover,
hyperuricemia can be an early marker of cardiovascular dysfunction
and the routine determination of circulating levels of sUA should be
implemented during risk stratification among children and adolescents.
Further larger studies and randomized trials are warranted to confirm
our findings.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2017.09.031.
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